Related Experiment Videos
Managing the transition to CFC-free inhalers
1Respiratory Centre, Portsmouth NHS Trust Hospitals.
Professional Nurse (London, England)
|September 13, 2000
Summary
Chlorofluorocarbon (CFC)-free inhalers will replace older asthma devices soon. New steroid-based inhalers improve drug delivery to the lungs, potentially enhancing treatment for small airway inflammation.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Pharmacology
Background:
- Asthma inhaler technology is transitioning away from chlorofluorocarbon (CFC) propellants.
- Current treatments may inadequately address inflammation in the small airways of the lungs.
- Newer inhaler formulations are being developed to improve therapeutic efficacy.
Purpose of the Study:
- To evaluate the lung deposition and penetration of novel CFC-free, steroid-based asthma inhalers.
- To compare the performance of new inhaler devices with older CFC-based inhalers.
- To assess the potential of these new inhalers to improve treatment of small airway inflammation.
Main Methods:
- Comparative analysis of lung deposition patterns.
- Assessment of peripheral lung penetration using advanced imaging or analytical techniques.
- Clinical evaluation of treatment efficacy in asthma patients (details not provided in abstract).
Main Results:
- CFC-free steroid-based inhalers demonstrated increased total lung deposition compared to previous devices.
- Enhanced penetration into the peripheral regions of the lungs was observed with the new inhalers.
- These findings suggest improved drug delivery to target sites.
Conclusions:
- The transition to CFC-free inhalers is imminent and supported by technological advancements.
- New steroid-based inhalers show promise for more effective treatment of asthma, particularly concerning small airway inflammation.
- Optimized lung deposition and penetration may lead to better asthma control.